RE:RE:RE:RE:Canaccord's Quarterly NASH Report I don't think it's just mixed messages, I think it's very different circumstances.
Oncology is straightforward, they ticked boxes in the preclinical and then got the outcome that would be expected when the boxes are ticked.
NASH is very different. When you get a PR like the Jan 7th one that says you got the greenlight from the FDA the next line in the PR you expect will say we'll be starting the trial in the coming months and lay out the nature of the trial. You don't expect a letter to proceed followed by 3 to 6 months of more talking. Anybody got examples where other companies did that? Delays like that in biotech are never usually harbingers of good news. The dream scenario of a straight Ph3 with both regulators onboard looks like a stretch now, maybe they can pull it off. Maybe there are less than dream scenarios that aren't much worse than the dream scenario and retain most of it's value that are still possible, that is my hope. Clearly the analysts think there are scenarios below that which would still be good for the company but which would represent a significant hit to the value, I can't rule them out either.
It's this uncertainty that gives the perception of mixed messages. The company wanted to raise cash so wanted to serve up the best possible scenario and were certainly doing that at the end of 2020 but the facts of the situation are far less clear than that. The letter to proceed clearly support their right to present that best case scenario but the ongoing issues (to me) clearly show that it's not the only outcome we should consider. Of course the company could help everybody in this process if they just talked about what the sticking points are.
scarlet1967 wrote: After the PR some legacy shareholders who were doubting the legitimacy of NASH felt more confident then after the dilution they start questioning it, after yesterday's comments they feel more comfortable. The confusion causes by mixed messages which are not only words but actions are why the SP is where it is despite the execution.
They need to align their actions and messaging and get out there selling the company to the retail and institutions.